← Leaderboards
Randall T Peterson
Massachusetts General Hospital
$17,953,472
Attributed
$26,362,431
Total exposure
17
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.4M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,541,566 · 19
By mechanism
U54$22,841,431 · 7
R01$15,887,490 · 6
U01$2,448,495 · 2
R24$1,538,650 · 1
R21$684,500 · 2
R13$141,000 · 1
Top collaborators
- Raymond J Peterson11 shared
- J. Keith Joung8 shared
- Calum A. Macrae6 shared
- Donald B Bloch5 shared
- Kenneth D Bloch5 shared
- Jing-Ruey Joanna Yeh4 shared
- Marco Bortolato2 shared
- James Alan Gagnon2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- J. Keith Joung$24,183,955
- Calum A. Macrae$21,291,852
- Chad Albert Cowan$12,486,126
- Philip K Liu$5,849,352
- Mathias Lichterfeld$34,368,889
Others in their field
Top investigators on “Zebrafish”
- Leonard I Zon · Children'S Hospital Boston$58,820,730
- Monte Westerfield · University Of Oregon$50,217,878
- Richard A Gibbs · Baylor College Of Medicine$49,965,365
- Karl Alexander Deisseroth · Stanford University$29,745,200
- William S Talbot · Stanford University$29,496,829
- Robert L Tanguay · Oregon State University$27,361,484
Research focus
ZebrafishIn VivoBaseResearch PersonnelLeadTechnologyPhenotypePathway InteractionsGenerationsCyanidesToxic EffectInnovationCellsDesignMetabolomicsProgramsSmall MoleculeAnimal ModelScienceInsightExposure ToCommunitiesDrug DevelopmentMetabolic
Grant awards (74)
Multimodal phenotyping of zebrafish models of human disease$769,325
R24 · FY2025 · OD · contact PI
ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS$461,081
R01 · FY2025 · GM · contact PI
Multimodal phenotyping of zebrafish models of human disease$769,325
R24 · FY2024 · OD · contact PI
ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS$461,081
R01 · FY2024 · GM · contact PI
17th Annual Counteract Network Symposium$141,000
R13 · FY2024 · NS
Advancing Novel Cyanide Countermeasures$3,104,744
U54 · FY2023 · NS
ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS$461,081
R01 · FY2023 · GM · contact PI
Project 2: Advancing glyoxylate as a chemical countermeasure$388,093
U54 · FY2023 · NS · contact PI
Training & Education Core$388,093
U54 · FY2023 · NS · contact PI
Advancing Novel Cyanide Countermeasures$3,193,764
U54 · FY2022 · NS
Project 2: Advancing glyoxylate as a chemical countermeasure$506,903
U54 · FY2022 · NS · contact PI
ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS$470,351
R01 · FY2022 · GM · contact PI
Training & Education Core$220,622
U54 · FY2022 · NS · contact PI
Advancing novel cyanide countermeasures$3,197,049
U54 · FY2021 · NS
ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS$470,351
R01 · FY2021 · GM · contact PI
Project 2: Advancing glyoxylate as a chemical countermeasure$370,586
U54 · FY2021 · NS · contact PI
Exploring steroid-based therapies to reduce opioid abuse$190,625
R21 · FY2021 · DA
Training & Education Core$138,231
U54 · FY2021 · NS · contact PI
Advancing novel cyanide countermeasures$3,209,373
U54 · FY2020 · NS
ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS$470,351
R01 · FY2020 · GM · contact PI
Project 2: Advancing glyoxylate as a chemical countermeasure$372,906
U54 · FY2020 · NS · contact PI
Exploring steroid-based therapies to reduce opioid abuse$228,750
R21 · FY2020 · DA
Training & Education Core$139,097
U54 · FY2020 · NS · contact PI
Advancing novel cyanide countermeasures$3,249,958
U54 · FY2019 · NS
ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS$483,476
R01 · FY2019 · GM · contact PI
Project 2: Advancing glyoxylate as a chemical countermeasure$392,032
U54 · FY2019 · NS · contact PI
Training & Education Core$146,229
U54 · FY2019 · NS · contact PI
Modulation of Hepcidin-Ferroportin Signaling using Small Molecules$502,260
R01 · FY2018 · DK
Modulation of Hepcidin-Ferroportin Signaling using Small Molecules$502,260
R01 · FY2017 · DK
ADVANCING GENE-EDITING NUCLEASES FOR TARGETED GENOME MANIPULATION$561,811
R01 · FY2016 · GM
Modulation of Hepcidin-Ferroportin Signaling using Small Molecules$502,260
R01 · FY2016 · DK
Optimizing novel cyanide countermeasures$376,561
U54 · FY2016 · NS · contact PI
Training and Education Core$284,148
U54 · FY2016 · NS · contact PI
Optimizing novel cyanide countermeasures$150,000
U54 · FY2016 · NS · contact PI
ADVANCING GENE-EDITING NUCLEASES FOR TARGETED GENOME MANIPULATION$561,811
R01 · FY2015 · GM
Modulation of Hepcidin-Ferroportin Signaling using Small Molecules$502,260
R01 · FY2015 · DK · contact PI
Optimizing novel cyanide countermeasures$376,262
U54 · FY2015 · NS · contact PI
Training and Education Core$336,273
U54 · FY2015 · NS · contact PI
ADVANCING GENE-EDITING NUCLEASES FOR TARGETED GENOME MANIPULATION$561,811
R01 · FY2014 · GM
Modulation of Hepcidin-Ferroportin Signaling using Small Molecules$502,260
R01 · FY2014 · DK · contact PI
Optimizing novel cyanide countermeasures$375,311
U54 · FY2014 · NS · contact PI
Training and Education Core$284,112
U54 · FY2014 · NS · contact PI
Optimizing novel cyanide countermeasures$562,059
U54 · FY2013 · NS · contact PI
ADVANCING GENE-EDITING NUCLEASES FOR TARGETED GENOME MANIPULATION$561,811
R01 · FY2013 · GM
Training and Education Core$402,409
U54 · FY2013 · NS · contact PI
ADVANCING ZINC FINGER NUCLEASES FOR TARGETED GENOME MANIPULATION$563,606
R01 · FY2012 · GM
BMP inhibitors and the study of disease mechanisms in anemia of inflammation$454,289
R01 · FY2012 · DK · contact PI
Training and Education Core$360,797
U54 · FY2012 · NS · contact PI
In Vivo Discovery of Psychotropic Drugs by High-Throughput Behavioral Phenotyping$350,460
R01 · FY2012 · MH · contact PI
Optimizing novel cyanide countermeasures$315,819
U54 · FY2012 · NS · contact PI
ADVANCING ZINC FINGER NUCLEASES FOR TARGETED GENOME MANIPULATION$563,607
R01 · FY2011 · GM
BMP inhibitors and the study of disease mechanisms in anemia of inflammation$458,655
R01 · FY2011 · DK · contact PI
In Vivo Discovery of Psychotropic Drugs by High-Throughput Behavioral Phenotyping$350,460
R01 · FY2011 · MH · contact PI
ADVANCING ZINC FINGER NUCLEASES FOR TARGETED GENOME MANIPULATION$573,296
R01 · FY2010 · GM
BMP inhibitors and the study of disease mechanisms in anemia of inflammation$498,456
R01 · FY2010 · DK · contact PI
Rapid development of in vivo models for countermeasure discovery: organophosphate$393,437
U01 · FY2010 · NS · contact PI
Rapid development of in vivo models for countermeasure discovery: organophosphate$393,437
U01 · FY2010 · NS · contact PI
In Vivo Discovery of Psychotropic Drugs by High-Throughput Behavioral Phenotyping$354,000
R01 · FY2010 · MH · contact PI
BMP inhibitors and the study of disease mechanisms in anemia of inflammation$73,878
R01 · FY2010 · DK · contact PI
ADVANCING ZINC FINGER NUCLEASES FOR TARGETED GENOME MANIPULATION$570,098
R01 · FY2009 · GM
BMP inhibitors and the study of disease mechanisms in anemia of inflammation$486,185
R01 · FY2009 · DK · contact PI
Rapid development of in vivo models for countermeasure discovery: organophosphate$381,696
U01 · FY2009 · NS · contact PI
Rapid development of in vivo models for countermeasure discovery: organophosphate$381,696
U01 · FY2009 · NS · contact PI
In Vivo Discovery of Psychotropic Drugs by High-Throughput Behavioral Phenotyping$353,500
R01 · FY2009 · MH · contact PI
High-throughput behavioral screening for in vivo discovery of neuroactive drugs$265,125
R21 · FY2009 · MH · contact PI
Rapid development of in vivo models for countermeasure discovery: organophosphate$449,115
U01 · FY2008 · NS · contact PI
Rapid development of in vivo models for countermeasure discovery: organophosphate$449,114
U01 · FY2008 · NS · contact PI
CHEMICAL TOOLS FOR DISSECTION OF BLOOD VESSEL IDENTITY$373,347
R01 · FY2008 · HL · contact PI
Chemical genetic modifiers of acute myelogenous leukemia$223,027
R01 · FY2008 · CA · contact PI
CHEMICAL TOOLS FOR DISSECTION OF BLOOD VESSEL IDENTITY$373,347
R01 · FY2007 · HL · contact PI
Chemical genetic modifiers of acute myelogenous leukemia$223,027
R01 · FY2007 · CA · contact PI
CHEMICAL TOOLS FOR DISSECTION OF BLOOD VESSEL IDENTITY$384,498
R01 · FY2006 · HL · contact PI
Chemical genetic modifiers of acute myelogenous leukemia$229,688
R01 · FY2006 · CA · contact PI
CHEMICAL TOOLS FOR DISSECTION OF BLOOD VESSEL IDENTITY$393,750
R01 · FY2005 · HL